Teva regains investment-grade rating from Fitch

Fitch pointed to expected growth from drugs including Austedo and Ajovy; Teva is still rated below investment grade by S&P Global Ratings, at BB+ with a stable outlook, and by Moody’s, at Ba1 with a positive outlook

Raccontata daynetnews.com